Advertisement
News
Advertisement

Reportlinker Adds Triple Analysis: Colorectal Cancer, Lung Cancer and Lymphoma

Thu, 03/24/2011 - 4:33am
Bio-Medicine.Org

NEW YORK, March 24, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Triple Analysis: Colorectal Cancer, Lung Cancer and Lymphoma

http://www.reportlinker.com/p0284975/Triple-Analysis-Colorectal-Cancer-Lung-Cancer-and-Lymphoma.html

This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Lung Cancer and Lymphoma. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer

The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.

This part is based on the following publication:

A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Lung Cancer

The lung cancer report part includes defined and up to date development strategies for 283 lung cancer therapeutic drugs (>317 projects) within the portfolio of 167 investigators, from Ceased to Marketed. In total the report assesses three di

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading